A summary of equity-based compensation expense for continuing operations recognized during the three and nine months ended June 30, 2026 and 2025 is as follows:


	Three Months Ended June 30,				Nine Months Ended June 30,
	2026		2025		2026		2025
Stock options	$	2,414	$	1,610	$	5,615	$	5,435
Restricted stock units	2,722		3,269		9,318		6,595
Equity-based compensation expense	$	5,136	$	4,879	$	14,933	$	12,030

In connection with the sale of the Healthcare RCM Business, $2,517 and $3,112 of the Company's equity-based compensation expense was classified within "net income from discontinued operations" in the accompanying condensed consolidated statements of operations during three and nine months ended June 30, 2025, respectively.

Amounts are included in other costs of services and in selling, general and administrative expense on the condensed consolidated statements of operations.

Share-based compensation expense includes the estimated effects of forfeitures, which will be adjusted over the requisite service period to the extent actual forfeitures differ or are expected to differ from such estimates.

A summary of stock option activity for the nine months ended June 30, 2026 is as follows:


	Stock Options	Weighted Average Exercise Price
Outstanding at September 30, 2025	7,881,236	$	24.61
Granted	1,245,000	23.61
Exercised	(195,032)	23.18
Forfeited and cancelled	(140,638)	26.59
Outstanding at June 30, 2026	8,790,566	$	24.47

Exercisable at June 30, 2026	6,765,894	$	24.94

The weighted-average grant date fair value of stock options granted during the nine months ended June 30, 2026 was $12.41.

As of June 30, 2026, there were 8,790,566 stock options outstanding, of which 6,765,894 were exercisable. As of June 30, 2026, total unrecognized compensation expense related to unvested stock options, including an estimate for pre-vesting forfeitures, was $18,042, which is expected to be recognized over a weighted-average period of 3.4 years.

The total fair value of stock options that vested during the three and nine months ended June 30, 2026 was $187 and $5,024, respectively.

The Company has issued Class A common stock in the form of restricted stock units ("RSUs") under the 2018 Plan.

A summary of activity related to restricted stock units for the nine months ended June 30, 2026 is as follows:


	Restricted Stock Units	Weighted Average Grant Date Fair Value
Outstanding at September 30, 2025	1,160,641	$	24.89
Granted	405,826	24.01
Vested	(409,714)	24.77
Forfeited and cancelled	(79,175)	24.49
Outstanding at June 30, 2026	1,077,578	$	24.63

The weighted-average grant date fair value of RSUs granted during three and nine months ended June 30, 2026 was $24.01.

As of June 30, 2026, total unrecognized compensation expense related to unvested RSUs, including an estimate for pre-vesting forfeitures, was $18,210, which is expected to be recognized over a weighted average period of 2.5 years.

The total fair value of RSUs that vested during the three and nine months ended June 30, 2026 was $455 and $10,148, respectively.